Core Insights - Shenzhen YHLO Biotech Co., Ltd. has made significant strides in the field of industry-academia-research collaboration by establishing two joint laboratories with Hong Kong University of Science and Technology (Shenzhen) and Shenzhen Technology University, focusing on neurological diagnosis and intelligent diagnostics [2][3] Group 1: Joint Laboratories - The "Neurodiagnosis Joint Laboratory" will focus on major neurodegenerative diseases such as Alzheimer's and Parkinson's, conducting systematic research on disease biomarkers, diagnostic technology development, and key equipment research [3] - The "Intelligent Diagnosis and Precision Medicine Joint Laboratory" will concentrate on AI image recognition systems, microfluidic detection platforms, and the exploration of new biomarkers, aiming to develop key technologies in intelligent diagnostics and precision medicine [3] Group 2: Strategic Goals - Both laboratories aim to convert core research outcomes into marketable products within 3 to 5 years while cultivating innovative and practical talent [3] - The establishment of these laboratories reflects YHLO's commitment to a clinical demand-oriented and industry transformation-focused collaboration logic [3][4] Group 3: Long-term Collaboration - YHLO's Chairman and CEO emphasized that the collaboration with universities is not just about project alignment but also about systematic and institutional long-term cooperation [4] - The joint laboratories are expected to facilitate a full chain from frontier research to technology development, product transformation, and clinical application, ultimately benefiting patients [4][5]

Group 1 - The core viewpoint of the news is that Aihua Long has established two joint laboratories with universities in Shenzhen, focusing on neurological diagnosis and intelligent diagnosis, which signifies the company's commitment to advancing its capabilities in the in vitro diagnostics and life health sectors [1][2][3] Group 2 - The "Neurodiagnosis Joint Laboratory" with the Chinese University of Hong Kong (Shenzhen) will focus on major neurodegenerative diseases such as Alzheimer's and Parkinson's, conducting systematic research on disease biomarkers, diagnostic technology, and key equipment development [1] - The "Intelligent Diagnosis and Precision Medicine Joint Laboratory" with Shenzhen Technology University will concentrate on AI image recognition systems, microfluidic detection platforms, and the development of new biological markers, aiming to convert core R&D results into marketable products within 3 to 5 years [2] - Aihua Long's collaboration with these universities reflects a strategy of integrating clinical needs with industrial transformation, emphasizing a systematic and institutional long-term cooperation model [2][3] - The establishment of these laboratories is expected to enhance Aihua Long's product line and technical reserves, contributing to the high-quality development of the biopharmaceutical industry in the Guangdong-Hong Kong-Macao Greater Bay Area [3] - The company aims to create a comprehensive innovation ecosystem in the health industry through the integration of research, technology development, product transformation, and clinical application [2][3]

Group 1 - On January 19, Shenzhen Aihuilong Biotechnology Co., Ltd. (Aihuilong, 688575.SH) established two joint laboratories with Hong Kong University of Science and Technology (Shenzhen) and Shenzhen Technology University, focusing on neurological disease diagnosis and intelligent diagnosis and precision medicine [1][2] - The "Neurodiagnosis Joint Laboratory" will focus on early diagnosis and treatment of neurological diseases, particularly Alzheimer's and Parkinson's diseases, addressing the challenges in the diagnosis of neurological disorders [4][8] - The "Intelligent Diagnosis and Precision Medicine Joint Laboratory" aims to develop AI image recognition systems, microfluidic detection platforms, and new biomarkers, leveraging the strengths of both universities and Aihuilong's market experience [5][7] Group 2 - Aihuilong's collaboration with two universities reflects its commitment to integrating clinical needs with industrial transformation, emphasizing a systematic and long-term partnership approach [8] - The establishment of these laboratories is expected to enhance Aihuilong's product line and technical reserves, contributing to the high-quality development of the biopharmaceutical industry in the Guangdong-Hong Kong-Macao Greater Bay Area [8] - The joint laboratories will facilitate a comprehensive approach from cutting-edge research to clinical application, aiming to create an innovative ecosystem in the health industry [8]